Featured news from NHIVNA

HIV-related news from NAM

Dolutegravir monotherapy fails to maintain HIV viral suppression, but dolutegravir + lamivudine looks good
Liz Highleyman, 2017-03-09 10:00:00

Dolutegravir used alone without other antiretrovirals was unable to keep viral load suppressed in some people who switched from a standard three-drug combination regimen, according to research presented at the 2017 Conference on Retroviruses and Opportunistic Infections (CROI) last month in Seattle. But evidence continues to show that dolutegravir plus a single other drug can work well as maintenance therapy.

In an effort to make antiretroviral therapy (ART) more convenient, better tolerated and less expensive, researchers have tried to simplify HIV treatment by reducing the number of drugs in maintenance regimens for people who have achieved undetectable viral load on multi-drug combinations.

Dolutegravir (Tivicay) is a potent and well tolerated integrase inhibitor with a high genetic barrier to resistance, making it a good candidate for simplified therapy.